Hikma Pharmaceuticals PLC - Back to Homepage

Keep yourself updated about Hikma

News Search

Search for a news item according to period of time or category.

Ensuring the Sustainability of our Business

Download Hikma's latest CR Report

24 July 2014

Hikma agrees to acquire Ben Venue manufacturing site adding R&D capabilities and capacity

London, 24 July 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has agreed with Ben Venue Laboratories, Inc. ("Ben Venue"), part of the Boehringer Ingelheim Group of Companies, to acquire substantially all of the assets of their generic injectables manufacturing site in Bedford, Ohio. The acquisition is pursuant to the exclusivity arrangement entered into on 28 May 2014. No incremental consideration is payable in relation to Hikma acquiring the Ben Venue manufacturing site.

London, 24 July 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has agreed with Ben Venue Laboratories, Inc. ("Ben Venue"), part of the Boehringer Ingelheim Group of Companies, to acquire substantially all of the assets of their generic injectables manufacturing site in Bedford, Ohio. The acquisition is pursuant to the exclusivity arrangement entered into on 28 May 2014. No incremental consideration is payable in relation to Hikma acquiring the Ben Venue manufacturing site.

The Ben Venue manufacturing site includes four manufacturing plants and a Quality and Development Centre ("QDC") with excellent capabilities.  The QDC, which includes a R&D pilot plant and a team of experienced employees, will significantly strengthen Hikma's existing R&D capabilities, support the development of a strong future pipeline and expedite the transfer and reactivation of recently acquired ANDAs.

All manufacturing at the Ben Venue site was ceased in December. Over time, Hikma will evaluate the potential to partially reactivate the site to support the delivery of its medium and long term growth plans. In the short term, Hikma will transfer certain modern, advanced equipment, including lyophilisers and filling lines, to its other global manufacturing facilities in the US and Europe, significantly increasing its current injectable manufacturing capacity and capabilities.

The gross assets subject to the transaction, prior to the performance of the fair value exercise and excluding acquired intangible assets, have a book value of $4 million.1 The acquisition of the Ben Venue manufacturing site is subject to customary approvals in the United States.

The guidance previously provided on 28 May 2014 remains unchanged. The acquisition of assets of Bedford, including the Ben Venue site, is expected to be slightly dilutive to adjusted2 earnings per share in 2014 and 2015 and strongly accretive to adjusted earnings per share from 2016 onwards.

Said Darwazah, Chairman and Chief Executive Officer of Hikma commented:
"I am very pleased to be acquiring the Ben Venue manufacturing site and their talented R&D team. We believe this will meaningfully enhance our R&D capabilities and enable us to significantly expand future capacity. This reflects Hikma's commitment to the long term growth of our fast growing global Injectables business and will create significant strategic value.”

--  ENDS  --

1 The book value of the gross assets in the financial statements of Ben Venue Laboratories, Inc at 31 December 2013
2 Before the amortisation of intangibles (excluding software)

Enquiries

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Director of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting  
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

+ more
Print page

Corporate

15 July 2014

Hikma completes the acquisition of assets of Bedford Laboratories

London, 15 July 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has completed its acquisition of assets of the US generic injectables business, Bedford Laboratories ("Bedford") from Ben Venue Laboratories, Inc., a member of the Boehringer Ingelheim Group of Companies.  As previously announced, the total consideration of up to $300 million will be satisfied through an upfront cash payment of $225 million and contingent cash payments of up to $75 million, subject to the achievement of performance-related milestones over a period of five years.

London, 15 July 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has completed its acquisition of assets of the US generic injectables business, Bedford Laboratories ("Bedford") from Ben Venue Laboratories, Inc., a member of the Boehringer Ingelheim Group of Companies.  As previously announced, the total consideration of up to $300 million will be satisfied through an upfront cash payment of $225 million and contingent cash payments of up to $75 million, subject to the achievement of performance-related milestones over a period of five years.

Hikma is acquiring Bedford’s large product portfolio, intellectual property rights, contracts for products marketed under license, raw material inventories, a strong R&D and business development pipeline and a number of employees across key business functions.  The combination of these assets with Hikma’s existing global Injectables platform will significantly strengthen Hikma’s position as a leading generic injectables company in the US.

In addition, Hikma has an exclusivity arrangement with the Boehringer Ingelheim Group to potentially acquire substantially all of the assets of the Ben Venue manufacturing facility in Bedford, Ohio.  Due diligence is ongoing and any acquisition will be subject to customary approvals in the United States and the United Kingdom.

Said Darwazah, Chairman and Chief Executive Officer of Hikma commented:
"I am very excited to have completed this transaction, which will significantly increase the scale and scope of our US Injectables business.  Adding a large portfolio of high value, niche and differentiated products will strengthen our market position and Bedford's deep pipeline and impressive R&D capabilities will support our future growth strategy.  We believe that this transaction will deliver significant future value.”

--  ENDS  --

Enquiries

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Director of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting  
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 7831 3113

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

+ more
Print page

Corporate

28 May 2014

Hikma Pharmaceuticals PLC – Acquisition of Bedford Laboratories

London, 28 May 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has signed an asset purchase agreement with Ben Venue Laboratories, Inc., a member of the Boehringer Ingelheim Group of Companies, to acquire assets of Bedford Laboratories (“Bedford”), its US generic injectables business, for a total consideration of up to $300 million, which will be satisfied through an upfront cash payment of $225 million. A further $75 million in contingent cash payments will be paid, subject to the achievement of performance-related milestones, over a period of five years. In addition, Hikma has entered into an exclusivity arrangement with the Boehringer Ingelheim Group to acquire substantially all of the assets of the Ben Venue manufacturing facility in Bedford, Ohio, one of the largest sterile injectable manufacturing sites in the world.

Hikma significantly strengthens its global Injectables business, acquiring assets of Bedford Laboratories

London, 28 May 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has signed an asset purchase agreement with Ben Venue Laboratories, Inc., a member of the Boehringer Ingelheim Group of Companies, to acquire assets of Bedford Laboratories (“Bedford”), its US generic injectables business, for a total consideration of up to $300 million, which will be satisfied through an upfront cash payment of $225 million. A further $75 million in contingent cash payments will be paid, subject to the achievement of performance-related milestones, over a period of five years. In addition, Hikma has entered into an exclusivity arrangement with the Boehringer Ingelheim Group to acquire substantially all of the assets of the Ben Venue manufacturing facility in Bedford, Ohio, one of the largest sterile injectable manufacturing sites in the world.

Bedford is a generic injectables company with the third largest portfolio of generic injectable products in the US.1 Under the agreement, Hikma is acquiring Bedford’s assets, including a large product portfolio, intellectual property rights, contracts for products marketed under license, raw material inventories, a strong R&D and business development pipeline and a number of employees across key business functions. 

The combination of these assets with Hikma’s existing global Injectables platform will significantly strengthen Hikma’s position as a leading generic injectables company in the US.

Transaction highlights

  • Helps to address critical supply shortages in the US market through the planned re-introduction of the acquired products
  • Delivers significant strategic value, adding a large portfolio, broad pipeline and experienced employee base to strengthen Hikma’s position as a leading generic injectables company in the US
  • Brings a broad range of complementary products, including a large oncology portfolio and a number of niche, differentiated products
  • Adds a unique and attractive R&D pipeline and a number of business development opportunities, along with experienced R&D and operational teams
  • Leverages Hikma’s US FDA approved injectable manufacturing capacity in the US, Portugal and Germany, as well as its expertise in sterile liquid, lyophilised and cytotoxic production, bringing scale benefits and cost synergies
  • Slightly dilutive to adjusted2 earnings per share (“EPS”) in 2014 and 2015, with strong EPS accretion thereafter as the acquired products are re-introduced to the market

Said Darwazah, Chief Executive Officer of Hikma commented:
“I am very excited to be making this strategically important investment in our Injectables business.  Bedford’s impressive product portfolio and deep pipeline will significantly increase the scale and scope of our rapidly growing US Injectables business.  The large number of high value, niche and differentiated products we are acquiring will strengthen our market position in the US and will benefit patients by bringing back products to the market that are currently in short supply.

Through our disciplined approach to M&A, we have established an excellent track record of making value enhancing acquisitions.  I am confident that we have the technical capabilities and manufacturing expertise to successfully re-launch the acquired products over the next few years and our success in integrating the MSI acquisition will help to ensure a smooth integration.  We remain committed to investing in the long term growth of our Injectables business and we believe that this transaction will deliver significant future value for the Group.”

Paul R. Fonteyne, US Country Managing Director, President and CEO of Boehringer Ingelheim USA Corporation, and Chairman, Ben Venue Board of Directors commented:
"We believe that this is a positive development, allowing Hikma to leverage its existing infrastructure and manufacturing capabilities to re-introduce important products to the US market, bringing significant benefit to patients.  For more than 20 years, Bedford Laboratories and its product portfolio have been of great value to patients, customers and the marketplace.  As part of Hikma, the Bedford team will remain focused on strengthening its relationships with customers and continuing to serve the needs of patients."

Strategic rationale

In 2013, Hikma’s global Injectables business generated revenue of $536 million and accounted for 39% of Group revenue.  Investing in the growth and development of this business has been a key strategic priority in recent years.  In May 2011, we completed the acquisition of Baxter’s Multi-Source Injectables business (“MSI”), which transformed our US Injectables business, establishing Hikma as the third largest supplier by volume in the US generic injectables market.  The large and fast growing US generic injectables market is valued at around $7.6 billion3 and offers significant future growth opportunities.  Our strategic focus within Injectables continues to be to increase our US market share by value through investment in a strong product portfolio and pipeline.

This acquisition marks another significant step towards achieving our ambitions in Injectables, adding a large portfolio of 84 products, which combined with Hikma’s 63 existing marketed products, creates the broadest portfolio of generic injectable products in the US market.4 Bedford’s portfolio spans a range of therapeutic categories and includes a large number of oncology products, as well as a number of niche, differentiated products.

Bedford also brings a unique and attractive R&D pipeline of 27 products, of which 16 are filed and pending approval from the US FDA.  The pipeline assets focus on higher value, medically necessary and acute care products, including numerous Paragraph IV opportunities.  The pipeline also includes several exciting business development projects, including licensing and co-development partnerships.

The acquisition will strengthen our current US operations, adding highly skilled employees across key business functions, such as R&D, sales and marketing, business development and regulatory affairs.  These employees will bring experience and expertise in US injectables and strengthen Hikma’s existing operations.

Hikma will be able to leverage its US FDA approved facilities in the US, Portugal and Germany to manufacture the acquired products, which we will begin transferring to Hikma’s sites immediately following closing the transaction.  We are targeting to transfer an initial tranche of around 20 products, which we expect to be able re-launch to the market between 2015 and 2017, with the potential to transfer further products thereafter.  The products will be prioritised based on the strength of the market need, the ease of transfer and the expected gross margin contribution.

In addition, Hikma has entered into an exclusivity arrangement with the Boehringer Ingelheim Group to potentially acquire substantially all of the assets of the Ben Venue manufacturing site in Bedford, Ohio, subject to due diligence and customary approvals in the United States and the United Kingdom.  These assets would significantly enhance Hikma’s existing global injectable manufacturing capabilities, adding one of the largest lyophilisation plants in the world and dedicated cytotoxic facilities.

Financial information

In 2013, the assets subject to the transaction generated revenue of $19 million and negative EBITDA of $22 million,5 which reflects the limited sales of Bedford’s products following manufacturing issues at its affiliate, Ben Venue, which halted production in 2013.  Hikma expects the acquired assets to generate limited revenue in 2014 and 2015 while products are being transferred to Hikma’s manufacturing sites.  By 2017, Hikma expects revenue from the acquired assets to have increased significantly to around $150 million, as the acquired products are re-launched and certain pipeline opportunities are realised, with strong growth potential thereafter.  The acquisition is expected to be slightly dilutive to adjusted6 EPS in 2014 and 2015 and strongly accretive to adjusted EPS from 2016 onwards.

The gross assets subject to the transaction, prior to the performance of the fair value exercise and excluding acquired intangible assets, have a book value of $65 million.7 They are primarily comprised of raw material inventories and will help to accelerate the re-launch of the acquired products to the market.  The transaction will be funded by new debt facilities.  We expect to complete the transaction in the second half of 2014, subject to customary regulatory approvals.

Following completion of this transaction, we will continue to have the financial flexibility to pursue further value enhancing opportunities across our businesses.

A conference call for analysts and investors will be held on 28 May 2014 at 14:00 BST on UK and international dial in: +44 (0) 20 3426 2890 or UK toll free dial in:  0808 237 0060.  A live webcast of the conference call will be available at www.hikma.com/en/investors.aspx.  A recording of the call will be available on the Hikma website.

Centerview Partners and Citigroup Global Markets Limited (“Citi”) acted as financial advisers to Hikma.  Citi and HSBC jointly led the arrangement of the financing.   White & Case LLP acted as lead counsel to Hikma.

Bank of America Merrill Lynch acted as the financial adviser, and Covington & Burling LLP acted as counsel, to Ben Venue.

--  ENDS  --

1. IMS Healthcare, CY December 2013 and Bedford management information
2. Before amortisation (excluding software) and integration costs
3. IMS Healthcare, MAT December 2013
4. IMS Healthcare, CY December 2013 and Bedford management information
5. Bedford management information.  Reflects carve-out adjustments and includes non-recurring items and other pro-forma adjustments
6. Before the amortisation of intangibles (excluding software)
7. Bedford management information.  Reflects carve-out adjustments

Enquiries

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Director of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting  
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 7831 3113

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

+ more
Print page

Corporate

15 May 2014

Interim Management Statement

London, 15 May 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, will hold its Annual General Meeting today where the following statement will be made regarding its current trading and financial position.

London, 15 May 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, will hold its Annual General Meeting today where the following statement will be made regarding its current trading and financial position. This constitutes its Interim Management Statement relating to the period from 1 January 2014 to date, as required by the UK Listing Authority’s Disclosure and Transparency Rules.

Hikma has made a strong start to the year and we are pleased to be reiterating our guidance for 2014 of around 5% Group revenue growth, following an exceptionally strong year in 2013. We are also very pleased that, through our ongoing commitment to the highest standards of quality manufacturing, we successfully returned our Eatontown facility to regulatory compliance earlier this year.

Branded
In the year to date, our Branded business has been performing in line with last year. We have been delivering strong growth in two of our largest markets, Saudi Arabia and Egypt, driven by new product launches. In other markets, such as Algeria and Sudan, we have seen a slower start to the year. We expect sales to accelerate across the region, driven by new product launches and our focus on improving the product mix. On a constant currency basis, we continue to expect revenue growth of around 10% in 2014 and adjusted operating margin in line with 2013.

Injectables
Our global Injectables business has continued to perform very well in the year to date, particularly in the US, where we continue to leverage our product portfolio to drive growth. The breadth of our portfolio is enabling us to gain market share in certain products and this is more than offsetting an increase in competition in other products. We expect this strong performance to continue and we reiterate our guidance of above 20% revenue growth for the global Injectables business for the full year. Given our strategic focus on higher value products, we are upgrading expectations for the adjusted operating margin to around 35%.

Generics
The Generics business has also made a good start to the year. In April, we received a close-out letter from the US Food and Drug Administration (“US FDA”) that lifted the warning letter in respect of our Eatontown facility in New Jersey. This reflects the investment we have made to complete the remediation work, upgrade our manufacturing processes and strengthen our operations. 

Revenue in the year to date has remained strong and we are benefitting from the re-introduction of products to the market. We continue to expect the Generics business to deliver revenue of around $170 million in 2014, with an adjusted operating margin of above 25%.

Financing position
Our financing position remains very strong and will allow us to make further strategic acquisitions and investments, as these opportunities arise. 

Said Darwazah, Chief Executive Officer of Hikma said:
“I am pleased that the Group has made a strong start to the year. Our efforts to build a broad portfolio of injectable products and continued focus on operational excellence are delivering results. We are delivering strong revenue growth and upgrading our guidance for the adjusted operating margin guidance for the Injectables business this year. 

Our diversified business in the MENA region has enabled us to maintain sales in the year to-date and the outlook for the business remains strong. Following our significant remediation efforts, we are very pleased to have successfully resolved the issues with our Eatontown facility. Our focus is now on rebuilding the portfolio and pipeline for this business. Overall, we are pleased with our performance in the year to date and are confident in the outlook for the full year.”

We will announce our interim results for the six months to 30 June 2014 on 20 August 2014.

--  ENDS  --

Enquiries

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Head of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting  
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 7831 3113

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million. 

+ more
Print page

Corporate

15 April 2014

Hikma Holds its 7th Volunteering Day

Amman, 15 April 2014 – Hikma Pharmaceuticals, the leading pharmaceutical company, held its 7th Global Volunteering Day in April, in all of its main manufacturing facilities worldwide. In Jordan, this celebration was held in collaboration with Tkiyet Um Ali, an initiative that provides food and services on daily basis to the less privileged sectors of Jordanian society.

Amman, 15 April 2014 – Hikma Pharmaceuticals, the leading pharmaceutical company, held its 7th Global Volunteering Day in April, in all of its main manufacturing facilities worldwide. In Jordan, this celebration was held in collaboration with Tkiyet Um Ali, an initiative that provides food and services on daily basis to the less privileged sectors of Jordanian society.

The annual volunteering day is part of Hikma’s continuous strategic corporate responsibility activities; it comes to emphasize the essential role of voluntary work in supporting various organizations to improve and strengthen societies, and to instill volunteering conduct in Hikma employees.

This year Hikma employees volunteered at Tkiyet Um Ali’s main warehouse and helped in preparing 400 food packages for passers-by. Moreover, Hikma will be supporting 35 families for a whole year through the provision of food packages on monthly basis.

“Our volunteers had a great sense of satisfaction as they were helping the needy and the hungry in obtaining their daily sustenance,” commented Hana Ramadan, VP of Communications at Hikma. She added “Hikma fully understands the importance of ensuring that all Jordanians are provided with the basics of survival, such as healthy food. At Hikma we provide high quality medications to ensure the general well being of humans and through this year’s collaboration we are addressing the malnutrition issue as well.”

+ more
Print page

CR

02 April 2014

Hikma announces successful resolution to US FDA warning letter at Eatontown facility

London, 2 April 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that we have received a close-out letter from the US Food and Drug Administration (“US FDA”) that lifts the warning letter received in February 2012 in respect of its Eatontown facility in New Jersey, which provides oral products for the US market.

London, 2 April 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that we have received a close-out letter from the US Food and Drug Administration (“US FDA”) that lifts the warning letter received in February 2012 in respect of its Eatontown facility in New Jersey, which provides oral products for the US market. This communication follows the US FDA’s re-inspection of the facility in February 2014 to complete its evaluation of the corrective actions we have taken in response to the warning letter. This successfully resolves all issues raised by the US FDA in February 2012 and all subsequent communications.

Said Darwazah, Chief Executive Officer of Hikma commented:
“I am pleased to report that we have brought the Eatontown facility back into compliance with the US FDA. The investment we have made to complete the remediation work, upgrade our manufacturing processes and strengthen our operations, provides greater quality and support for our customers and we are committed to continuing to invest in the highest quality standards. We are gradually re-introducing products to the US market from the Eatontown facility, adding to the products we supply from our US FDA approved facilities in Jordan and Saudi Arabia. We believe there are an increasing number of attractive market opportunities for our Generics business and we are investing in our pipeline of oral and other non-injectable product forms, whilst continuing to look for further product acquisition opportunities.”

We expect the Generics business to deliver revenue of around $170 million in 2014, with an adjusted operating margin of above 25%.

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Head of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting  
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 7831 3113


About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

+ more
Print page

Corporate

31 March 2014

Hikma and AUB collaborate on developing anticancer treatment from medicinal plants

Beirut, March 2014 – Hikma has established a scientific collaboration with the American University of Beirut-Nature Conservation Center (AUB-NCC) in March 2014 to pioneer anticancer treatment from medicinal plants.

In addition to financial support, Hikma will help catapult these new potential treatments from the AUB laboratories to the market, thus making them accessible to the general public.

Beirut, March 2014 – Hikma has established a scientific collaboration with the American University of Beirut-Nature Conservation Center (AUB-NCC) in March 2014 to pioneer anticancer treatment from medicinal plants.

In addition to financial support, Hikma will help catapult these new potential treatments from the AUB laboratories to the market, thus making them accessible to the general public.

“After thorough evaluation of this opportunity we are excited to enter into such novel collaboration with AUB team,” said Dr. Ragheb Al-Shakhshir, Corporate Vice President of Research and Development. “This research has the potential to therapeutically exploit our rich Mediterranean flora and to identify and extract natural compounds to extend our existing oncology portfolio. Hikma R&D will work closely with AUBs’ multi-disciplinary team to identify, test and formulate these new molecules.”

The medicinal plants being studied were chosen after scouring folk medicine archives and identifying the most well-known 29 medicinal plants in Lebanon. This list was narrowed down to two really promising plant species , “Akhilia zat al-alf waraqah”, and “Shawk al-dardar,”, commonly known as yarrow and loggerheads or knapweed, respectively. The two plants were found effective against colon and skin cancer, they also show promising effects on leukemia and breast cancer.

Press Release
+ more
Print page

Product

29 March 2014

Hikma Pharmaceuticals supports and takes part in "Earth Hour 2014"

Amman, March 2014 – Hikma Pharmaceuticals sponsored the global campaign "Earth Hour 2014", which took place on Saturday March 29, and was organized by the Royal Society for the Conservation of Nature in Jordan. The sponsorship comes in light of Hikma’s commitment in raising awareness about environmental issues such as reducing energy consumption to save the earth and reduce the effects of climate change.

Amman, March 2014 – Hikma Pharmaceuticals sponsored the global campaign "Earth Hour 2014", which took place on Saturday March 29, and was organized by the Royal Society for the Conservation of Nature in Jordan. The sponsorship comes in light of Hikma’s commitment in raising awareness about environmental issues such as reducing energy consumption to save the earth and reduce the effects of climate change.

Official and civil organizations, hundreds of citizens, in addition to Hikma employees, gathered to celebrate the 2014 Earth Hour through joining a candlelit march for one hour in the streets of ​​Jabal Amman.

The event is held worldwide annually encouraging individuals, communities, households and businesses to turn off their non-essential lights for one hour, from 8:30 to 9:30 p.m., as a symbol for their commitment to the planet.

+ more
Print page

CR

Get adobe reader Most computers will open PDF documents automatically, but you may need to download Adobe Reader.